Dimerix

A clinical phase company with a powerful drug discovery technology

Gold Coast Investment Showcase

22 June 2017

Disclaimer

Some of the information in this presentation may refer to Dimerix Limited ("Dimerix" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision regarding Dimerix.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Dimerix, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Dimerix and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Dimerix is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Dimerix securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Dimerix, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Dimerix does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward looking statements

This presentation contains certain forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Dimerix to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Dimerix will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Dimerix and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Investment Highlights
Dimerix Limited (ASX:DXB)

Dimerix

1. Phase 2 clinical trial for a kind of chronic kidney disease (CKD) called FSGS
2. **New clinical data to be announced in July 2017 – a key value inflection point**
3. Relatively low cost and short timeframe of lead clinical program, DMX-200
4. Repurposed drugs (known safety) and Orphan Drug Designation (low cost) key factors
5. Further drug development and licensing opportunities using our patented Receptor-HIT platform technology

Corporate History

Dimerix

2004 - 2014

2004

THE UNIVERSITY OF WESTERN AUSTRALIA

- Dimerix spun out of UWA

2004 - 2014

- Pre-clinical and proof of concept laboratory work
- March 2014 COO appointed

2015 - 2017

2015

LISTED ASX

- Listed on ASX
- First patient enrolled DMX-200 Phase 2a
- Orphan drug designation
- AU and US patents granted

2016

- Positive FDA meeting
- Interim Phase 2a data announced
- Enrolment in Phase 2a complete
- Kathy Harrison appointed CEO
- Start commercial reformulation

2017

- Head of Drug Development appointed
- Japanese patent granted
- Engaged international clinicians
- Phase 2a data to be announced
- Phase 2b trial to commence

Experienced board and management

Dimerix

Dr James Williams – Executive Chairman

- Co-founder of Dimerix and iCeutica (acquired in 2011 and now with 3 FDA drug approvals)
- Co-founder and Investment Director of Yuuwa Capital ($40M venture fund)

David Franklyn – Director

- Experienced Director of ASX-listed companies in a variety of sectors
- Extensive experience in financial analysis, corporate advice, business management and IR

Kathy Harrison – Chief Executive Officer

- 20 years operational and strategic experience in drug development including at AMRAD, Cytopia Research Pty Ltd, Phosphagenics Ltd
- Registered Patent Attorney

Dr Sonia Poli – Director

- Former Senior Management at Hoffman la Roche and Executive at Addex Therapeutics
- 20 years international experience in small molecule drug development

Hugh Alsop – Director

- Accomplished and commercially-focused pharmaceutical and biotechnology executive
- Responsible for successful global commercialisation programs and NDA registrations

Dr Robert Shepherd – Head of Drug Development

- Drug developer with experience in a wide range of projects / therapeutic areas
- PhD in biomedical research, and background in finance and project management

Corporate Overview

Dimerix

Corporate Snapshot

ASX Code:	DXB
Share Price (20 Jun 17):	$.009
Market cap:	$16.5m
Cash (31 Mar 2017):	$2.8m
Shares on issue*:	1,829.9m

Major Shareholders

Mr Peter Meurs	17.33
Yodambao Pty Ltd	5.11
Mrs Wishney Sritharan Krishnarajah	2.47
White Family	2.21
SRV Custodians Pty Ltd	2.07
Pfleger Family	1.70
Jampaso Pty Ltd (Williams Family)	1.51

Share price history

Major spike in share price occurred around interim Phase 2a trial results in Oct 2016

* Unlisted Performance Shares: 75.0m; Options (expire 30Jun2017): 70.8m; Options (expire 31Dec2017): 17.9m; Options (ESOP):20m

Chronic kidney disease (CKD)

- CKD is a growing global health problem affecting over 10% of the population
- Damaged kidneys “leak” proteins into the urine. This is called proteinuria.
- Proteinuria is the most common symptom of the disease and can indicate changes in kidney function
- CKD gets progressively worse, with patients whose kidneys fail requiring dialysis or kidney transplant



Current Treatments

Dimerix

- First line therapy are drugs to reduce blood pressure, which can reduce proteinuria but does not stop progression to kidney failure
- In some types of kidney disease, patients are given a cocktail of drugs including immunosuppressants and steroids such as Prednisone, which have **side effects** and require **repeated treatment cycles**
- **There is a huge unmet medical need for a safe treatment which can significantly reduce proteinuria and prolong the life of the kidney**

Will in remission



Relapse from nephrotic syndrome

NEPHCURE®
Kidney International
Saving Kidneys • Saving Lives

Market opportunity

- CKD is a global health problem with 26 million patients in the US alone
- Growing in incidence due to large number of people living with obesity and diabetes
- Medicare spending on end stage renal disease in 2014 was USD $32.8 billion – a massive drain on the health care system
- **Independent analysts estimate FSGS drug sales to be worth USD $1 billion per annum in the US alone**



DMX-200 – lead product candidate

- DMX-200 is an ‘adjunct’ therapy – less complex development path
- Patients continue taking their standard of care medication (irbesartan) and add a second drug to this (propagermanium)
- Both drugs have been in use for many years, and their safety profile is well understood
- **Interim data on our Phase 2a safety study showed an encouraging safety profile**
- **A number of patients saw a clinically significant reduction in proteinuria**


news.com.au

National | World | Lifestyle | Travel | Entertainment | Technology | Finance | Sport

Dimerix positive interim analysis

OCTOBER 4, 2016 2:05PM

Newsbites Finance

finfeed

Dimerix has **clinical data from part A of its phase**

Data from 2

safety profi

Dimerix hits milestone in fight with kidney disease

Published on: Jun 6, 2016 | by finfeed

Dimerix (ASX:DMX), an Australian biotechnology company currently undergoing clinical-stage trials of its flagship drug DMX-200, has announced a significant milestone in reaching 10 patients.

DMX-200 combines irbesartan and propagermanium in the treatment of chronic kidney disease (CKD) and has been shown to improve the outcome of CKD by reducing proteinuria by more than 50% in animal tests.

DXB announced it is on track to report interim data from its DMX-200 Phase II trial in patients with CKD after accumulating 11 patients.

DMX-200 Development & licensing timeline

Dimerix

Activity	Q2 2017	Q3 2017	Q4 2017	2018	2019	2020
Phase 2a						
Manufacture of commercial tablet						
Human PK study **- commercial tablet**						
Phase 2b						
End of Phase 2 consultation with FDA						
Single pivotal Phase 3						
Licensing opportunities						

Current development activities

Future development activities

Competitive landscape for FSGS

Dimerix

Retrophin®

- **NASDAQ: RTRX**
- **Market cap : ~US$ 674million**
- Phase 2 asset, sparsentan, for treating FSGS – a dual angiotensin endothelin receptor blocker

CHEMOCENTRYX

- **NASDAQ: CCXI**
- **Market Cap: ~US$ 355 million**
- Completed Phase 2 for CCX140 in diabetic nephropathy – a CCR2 antagonist
- Vifor licensed CCX-140 from Chemocentryx with Phase 2 data for use *outside the US* for $50m upfront

Limited competition in a large market

Dimerix Receptor-HIT platform

Receptor-HIT

- Patented tool that enables understanding of receptor interactions
- Particularly suited to GPCRs – most targeted receptor class for drug discovery
- Can identify **new uses** for existing drugs and drive the **discovery** of new drugs and research programs



Global pharmaceutical companies need access to Receptor-HIT technology to develop safe new drugs

Investment Highlights
Dimerix Limited (ASX:DXB)

Dimerix

1. Phase 2 clinical trial for a kind of chronic kidney disease (CKD) called FSGS
2. **New clinical data to be announced in July 2017 – a potential value inflection point**
3. Relatively low cost and short timeframe of lead clinical program, DMX-200
4. Repurposed drugs (known safety) and Orphan Drug Designation (low cost) key factors
5. Further drug development and licensing opportunities using our patented Receptor-HIT platform technology



Contact

Kathy Harrison
Chief Executive Officer
+61 419 359 149
kathy.harrison@dimerix.com

Dimerix Limited
ACN 001 285 230
www.dimerix.com